Journal article
54 Genes preserving stem cell state in Group 3 MB BTICs contribute to therapy evasion and relapse
Abstract
Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Current clinical trials for recurrent MB patients based on genomic profiles of primary, treatment-naïve tumors, provide limited clinical benefit since recurrent metastatic MBs are highly genetically divergent from their primary tumors. By adapting the existing Children’s Oncology Group treatment protocol for children with newly diagnosed high-risk MB for treatment of mice …
Authors
Bakhshinyan D; Vijayakumar T; Venugopal C; Adile AA; Singh M; Qazi M; Mahendram S; Manoranjan B; McFarlane N; Kameda-Smith M
Journal
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, Vol. 45, No. S3, pp. s13–s13
Publisher
Cambridge University Press (CUP)
Publication Date
6 2018
DOI
10.1017/cjn.2018.296
ISSN
0317-1671